AmanMG, ArnoldMD, EugeneL., McDougleCJ, VitielloB, ScahillL, DaviesM, McCrackenJT, TierneyE, NashPL, PoseyDJ, ChuangS, MartinA, ShahB, GonzalezNM, SwiezyNB, RitzL, KoenigK, McGoughJ, GhumanJK, LindsayRL: Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol, 15:869–884, 2005.
2.
AmanMG, SinghNN, StewartAW, FieldCJ: The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic, 89:485–491, 1985.
3.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000.
4.
AndersonLT, CampbellM, GregaDM, PerryR, SmallAM, GreenWH: Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry, 141:1195–202, 1984.
5.
CampbellM, AndersonLT, MeierM, CohenIL, SmallAM, SamitC, SacharEJ: A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry, 1978; 17:640–655.
6.
ChavezB, Chavez–BrownM, SopkoMAJr., ReyJA: Atypical antipsychotics in children with pervasive developmental disorders. Paediatr Drugs, 9:249–266, 2007.
CohenIL, CampbellM, PosnerD, SmallAM, TriebelD, AndersonLT: Behavioral effects of haloperidol in young autistic children. An objective analysis using a within-subjects reversal design. J Am Acad Child Psychiatry, 19:665–677, 1980.
9.
DoyleCA, McDougleCJ: Pharmacotherapy to control behavioral symptoms in children with autism. Expert Opin Pharmacother, 13:1615–1629, 2012.
10.
Lord CRM, Le CouteurA: Autism Diagnostic Interview–Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord, 24:659–685, 1994.
11.
McCrackenJT, McGoughJ, ShahB, CroninP, HongD, AmanMG, ArnoldLE, LindsayR, NashP, HollwayJ, McDougleCJ, PoseyD, SwiezyN, KohnA, ScahillL, MartinA, KoenigK, VolkmarF, CarrollD, LancorA, TierneyE, GhumanJ, GonzalezNM, GradosM, VitielloB, RitzL, DaviesM, RobinsonJ, McMahonD; Research Units on Pediatric Psychopharmacology Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med., 347:314–321, 2002.
12.
McDougleCJ, HolmesJP, CarlsonDC, PeltonGH, CohenDJ, PriceLH: A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry, 55: 633–641, 1998.
13.
NaruseH, NagahataM, NakaneY, ShirahashiK, TakesadaM, YamazakiK: A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatr, 48:173–184, 1982.
14.
OwenR, SikichL, MarcusRN, Corey–LisleP, ManosG, McQuadeRD, CarsonWH, FindlingRL: Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124:1533–1540, 2009.
15.
SheaS, TurgayA., CarrollA., SchulzM., OrlikH., SmithI., DunbarF: Ripseridone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114:634–641, 2004.
